The recent sell off in the stock market has also put a damper on the market for initial public offerings (IPO), which was finally starting to show a nascent recovery after a dismal showing in 2009. (Learn more about the IPO market, see: The Murky Waters Of The IPO Market.)
Over the last two years, the IPO market slowed dramatically, due to the fall in the stock market and risk aversion by investors. In 2007, 272 IPO deals came to market, raising $60 billion. Only 43 IPOs were priced in 2008, raising $28 billion, followed by 63 in 2009, raising an even lower $21.9 billion.

The low point was the first quarter of 2009, when only one deal was priced. Mead Johnson (NYSE:MJN), which was spun out by Bristol-Myers Squibb (NYSE:BMY), sold shares at $24 per share. That turned out to be one of the best deals in recent memory, as the stock is selling near $46, close to a 100% return in a year.

Things started to pick up toward the end of 2009. The fourth quarter saw 32 IPOs come to market, followed by seven in January, 2010.

IN PICTURES: 7 Forehead-Slapping Stock Blunders

Current Problems
The market sell off has changed the tone of the market. Terreno Realty has cut its offering size twice in the last two weeks. The company was originally scheduled to sell 15 million shares at $20 per share, but cut that to 10 million shares in January, 2010. The company is now reportedly offering 8.75 million shares, raising approximately $175 million.

Terreno Realty is a real estate investment trust (REIT) that intends to use the funds to acquire industrial properties in six coastal areas in the United States.

Many companies that filed for IPOs didn't even make it as far as Terreno Realty, as several postponed deals. Patriot Risk Management, which provides worker's compensation insurance, postponed its deal for a week, after cutting the pricing range from $12-8 per share.

Imperial Capital, an investment bank headquartered in California, shelved its IPO due to market conditions.

Current Successes
One of the few success stories so far in 2010 is Ironwood Pharmaceuticals (Nasdaq:IRWD), a biotechnology company that is developing a drug to treat irritable bowel syndrome. The company priced its deal in early February, selling 16.67 million shares at $11.25 per share, below the expected range of $14-16.

In November 2009, Ironwood Pharmaceuticals announced successful Phase III clinical trial results for Linaclotide. The company is developing the drug in partnership with Forest Labs (NYSE:FRX)

The Bottom Line
The IPO market, which started to rebound late last year as confidence returned to equity markets, may be in for a tougher road than many thought, as the IPO market gets caught up in the recent market sell off.

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Investing News

    Who Does Cheap Oil Benefit? See This Stock (DG)

    Cheap oil won't benefit most companies, but this retailer might buck that trend.
  2. Economics

    Can the Market Predict a Recession?

    Is a bear market an indication that a recession is on the horizon?
  3. Investing

    How to Ballast a Portfolio with Bonds

    If January and early February performance is any guide, there’s a new normal in financial markets today: Heightened volatility.
  4. Stock Analysis

    Performance Review: Emerging Markets Equities in 2015

    Find out why emerging markets struggled in 2015 and why a half-decade long trend of poor returns is proving optimistic growth investors wrong.
  5. Investing

    Don't Freak Out Over Black Swans; Be Prepared

    Could 2016 be a big year for black swans? Who knows? Here's what black swans are, how they can devastate the unprepared, and how the prepared can emerge unscathed.
  6. Investing News

    Today's Sell-off: Are We in a Margin Liquidation?

    If we're in market liquidation, is it good news or bad news? That party depends on your timeframe.
  7. Investing News

    Bank Stocks: Time to Buy or Avoid? (WFC, JPM, C)

    Bank stocks have been pounded. Is this the right time to buy or should they be avoided?
  8. Stock Analysis

    Why the Bullish Are Turning Bearish

    Banks are reducing their targets for the S&P 500 for 2016. Here's why.
  9. Stock Analysis

    How to Find Quality Stocks Amid the Wreckage

    Finding companies with good earnings and hitting on all cylinders in this environment, although possible, is not easy.
  10. Chart Advisor

    How Are You Trading The Breakdown In Growth Stocks? (VOOG, IWF)

    Based on the charts of these two ETFs, bearish traders will start turning their attention to growth stocks.
RELATED FAQS
  1. When does a growth stock turn into a value opportunity?

    A growth stock turns into a value opportunity when it trades at a reasonable multiple of the company's earnings per share ... Read Full Answer >>
  2. What is the formula for calculating EBITDA?

    When analyzing financial fitness, corporate accountants and investors alike closely examine a company's financial statements ... Read Full Answer >>
  3. How do I calculate the P/E ratio of a company?

    The price-earnings ratio (P/E ratio) is a valuation measure that compares the level of stock prices to the level of corporate ... Read Full Answer >>
  4. How do you calculate return on equity (ROE)?

    Return on equity (ROE) is a ratio that provides investors insight into how efficiently a company (or more specifically, its ... Read Full Answer >>
  5. How do you calculate working capital?

    Working capital represents the difference between a firm’s current assets and current liabilities. The challenge can be determining ... Read Full Answer >>
  6. What is the formula for calculating the current ratio?

    The current ratio is a financial ratio that investors and analysts use to examine the liquidity of a company and its ability ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center